Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Daunorubicina" patented technology

Marker genes for screening of drug-induced toxicity in human cells and screening method using the same

InactiveUS20110118127A1Microbiological testing/measurementLibrary screeningDrug induced toxicityCardiotoxicity
The present invention relates to a marker gene for screening a drug inducing toxicity in human and a screening method using the same. More precisely, the invention relates to a microarray on which marker genes up-or down-regulated specifically by 16 drugs inducing pulmonary toxicity, teratogenicity, nephrotoxicity, cardiotoxicity or mutation (Methotrexate, Nitrofurantoin, Amiodarone, Carbamazepine, Valproic acid, Thalidomide, Cisplatin, Gentamycin, Amphotericine, Furylfuramide, N-nitroso-N-methylurea, methylmethanesulfonate, 4-nitroquinoline-N-oxide, 2-nitrofluorene, Doxorubicin and Daunorubicin) are integrated, a kit comprising the said microarray, and a screening method of a drug inducing toxicity in human using the same. The DNA microarray containing the marker gene of the present invention facilitates the construction of Toxtarget Array for screening a drug inducing toxicity in human using drug-specific genes, suggesting that this chip can be effectively used for monitoring drugs or chemicals carrying toxicity to human or determining risks thereof and also it can be used as a tool for examining mechanisms of toxicity / side effects caused by the drugs.
Owner:KOREA INST OF SCI & TECH

Preparation method of double-targeting acid-sensitive prussian blue drug delivery system and application thereof

The invention discloses a preparation method of a double-targeting acid-sensitive prussian blue drug delivery system and an application thereof, which can effectively solve the problems of leukemia drug resistance and liver and spleen infiltration. According to the technical scheme, the preparation method comprises the following steps: firstly, adsorbing acid-sensitive polyethylene glycol-polyethyleneimine macromolecules on the surfaces of Prussian blue nanoparticles through electrostatic interaction and hydrogen-bond interaction; secondly, the CXCR4 antagonistic polypeptide (E5) and hyaluronic acid are connected with polyethyleneimine molecules on the surfaces of the prussian blue nanoparticles through chemical bonds; thirdly, daunorubicin is adsorbed to the surfaces of the prussian bluenanoparticles through hydrogen bond interaction. The preparation method is simple and mild, materials are safe and easy to obtain, good biocompatibility is achieved, a prepared carrier has the blood long-circulation capacity, the tumor cell double-targeting capacity, the lysosome escape capacity and the acid-sensitive drug release capacity, the mouse leukemia treatment effect can be effectively enhanced, and bone marrow homing and liver and spleen infiltration are inhibited.
Owner:SOUTHEAST UNIV

Liposomal formulations of anthracycline agents and cytidine analogs

Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Owner:CELATOR PHARMA INC

Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes

Provided are compositions and methods for the treatment of hematological conditions, in particular CD99+ acute myelogenous leukemias (AML) and myelodysplastic syndromes (MDS), which comprise one or more antibody that (a) binds to the extracellular domain of CD99, (b) ligates AML and / or MDS cell-surface expressed CD99, (c) promotes the capping / clustering / aggregation AML and / or MDS cell-surface expressed CD99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated CD99+ AML and / or MDS cells. Disclosed methods include methods for identifying AML and MDS patients that are susceptible to treatment with an anti-CD99 antibody by detecting the elevated expression of CD99 in a tissue sample or cell from an AML or MDS patient and for treating an AML and / or MDS patient exhibiting elevated CD99 gene and or cell-surface protein expression by administering a composition comprising an anti-CD99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and an AML and / or MDS chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5-azacytidine, and decitabine.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Composition and method for reducing drug levels in tissues when orotate derivative is given

The invention relates to the field of reconstruction of drug chemical structure by preparation of orotate derivatives, and the drug is known to have side effect to cause tissue toxicity. More specifically, the invention relates to anthracycline, doxorubicin and daunorubicin orotate derivatives, and the orotate derivatives which and can reduce drug levels in non cancer tissues. The orotate derivatives are equally effective in inhibiting animal SCCAKI-1 renal tumor, and compared with doxorubicin hydrochloride, doxorubicin reduction in heart tissue shows that toxicity induced by production of anthracycline free radicals is reduced.
Owner:SAVVIPHARM INC

Daunorubicin-containing medicine, preparation method of daunorubicin-containing medicine, medical composition and application of daunorubicin-containing medicine

The application of the invention provides a daunorubicin-containing medicine, a preparation method of the daunorubicin-containing medicine, a medical composition and an application of the daunorubicin-containing medicine. The medicine comprises nucleic acid nanometer particles and daunorubicin, wherein the daunorubicin is mounted on the nucleic acid nanometer particles, the nucleic acid nanometerparticles comprise nucleic acid structural domains, the nucleic acid structural domains include an a sequence, a b sequence and a c sequence, the a sequence includes an a1 sequence or a sequence obtained in a manner that one or more basic groups of the a1 sequence are inserted, deleted or replaced, the b sequence includes a b1 sequence or a sequence obtained in a manner that one or more basic groups of the b1 sequence are inserted, deleted or replaced, and the c sequence includes a c1 sequence or a sequence obtained in a manner that one or more basic groups of the c1 sequence are inserted, deleted or replaced. According to the daunorubicin-containing medicine provided by the application of the invention, after the nucleic acid structural domains are subjected to target head modification, the daunorubicin-containing medicine has better target properties, can steadily deliver the daunorubicin, and is high in reliability.
Owner:BAI YAO ZHI DA BEIJING NANOBIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products